|
|
|
|
|
Thymosin ¥á1 Acetate |
|
C129H215N33O55 |
|
62304-98-7 |
|
It is clinically used to treat chronic hepatitis B and acts as the vaccine adjuvant of immunity impairer. |
|
Parameters of Product: 1 .Appearance :White powder 2 .Specific Optical Rotation(c=1,15%HAc) :-80.0~-95.0¡Æ 3 .Water Content(Karl Fischer) :¡Â5.0% 4 .Acetate Content(by HPLC) :¡Â10.0% 5 .Amino Acid Composition :¡¾10% of theoretical 6 .Purity (by HPLC) :¡Ã98.0% 7 .Single Impurity(by HPLC) :¡Â1.0% 8 .Peptide Content(by N%) :¡Ã82.0% 9 .Assay(By Anhydrous, Acetic Acid-free ) :95.0~102.0% 10 .Bacterial Endotoxins :¡Â5EU/mg
|
Industrial field |
pharmaceutical |
|
|
|
|
|
|
|
There are no existing companies to distribute selected chemical product |
|
|
|
|
|